Repositorio Dspace

Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation

Mostrar el registro sencillo del ítem

dc.contributor.author Rivera-Caravaca, José-Miguel
dc.contributor.author Marín, Francisco
dc.contributor.author Esteve-Pastor, María-Asunción
dc.contributor.author Gálvez, Josefa
dc.contributor.author Lip, Gregory-Y-H
dc.contributor.author Vicente, Vicente
dc.contributor.author Roldán-Schilling, Vanessa
dc.date.accessioned 2026-02-12T12:13:22Z
dc.date.available 2026-02-12T12:13:22Z
dc.date.issued 2019-12
dc.identifier.citation Rivera-Caravaca JM, Marín F, Esteve-Pastor MA, Gálvez J, Lip GYH, Vicente V, et al. Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation. BMJ Open. diciembre de 2019;9(12):e033712.
dc.identifier.issn 2044-6055
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/24345
dc.description.abstract INTRODUCTION: Atrial fibrillation (AF) is characterised by a high stroke risk. Vitamin K antagonists (VKAs) are the most commonly used oral anticoagulants (OACs) in Spain, but their efficacy and safety depend on the time in therapeutic range of International Normalized Ratio (INR) 2.0-3.0 over 65%-70%. Unfortunately, the difficulties of maintaining an optimal level of anticoagulation and the complications of VKAs (particularly haemorrhagic ones), frequently lead to cessation of this therapy, which has been associated with higher risk of adverse events (AEs), including ischaemic stroke. Our aims are as follows: (1) to evaluate the quality of oral anticoagulation with VKAs, the prevalence of poor quality of anticoagulation, and to identify factors predisposing to poor quality anticoagulation; and (2) to identify patients who will stop OAC and to investigate what factors influence the decision of OAC withdrawal. METHODS AND ANALYSIS: Prospective observational cohort study including outpatients newly diagnosed with AF and naïve for OACs from July 2016 to June 2018 in an anticoagulation clinic. Patients with prosthetic heart valves, rheumatic mitral valves or valvular AF will be excluded. Follow-up will extend for up to 3 years. During this period, the INR results and changes in the anticoagulant therapy will be recorded, as well as all AEs, or any other information that would be relevant to the proper conduct of research. ETHICS AND DISSEMINATION: All patients were informed about the nature and purpose of the study, and the protocol was approved by the Ethics Committee of Hospital General Universitario Morales Meseguer (reference: EST:20/16). This is an observational study focusing on 'real life' practice and therefore all treatments and follow-up will be performed in accordance to the routine clinical practice with no specific interventions or visits. The results of our study will be disseminated by presentations at national and international meetings, and publications in peer-reviewed journals.
dc.language.iso eng
dc.publisher BMJ PUBLISHING GROUP
dc.rights Atribución/Reconocimiento-NoComercial 4.0 Internacional *
dc.rights.uri http://creativecommons.org/licenses/by-nc/4.0/ *
dc.subject.mesh Administration, Oral
dc.subject.mesh Anticoagulants/administration & dosage/adverse effects/therapeutic use
dc.subject.mesh Atrial Fibrillation/drug therapy
dc.subject.mesh Hemorrhage/chemically induced
dc.subject.mesh Humans
dc.subject.mesh International Normalized Ratio
dc.subject.mesh Observational Studies as Topic
dc.subject.mesh Prospective Studies
dc.subject.mesh Research Design
dc.subject.mesh Spain
dc.subject.mesh Stroke/prevention & control
dc.subject.mesh Vitamin K/antagonists & inhibitors
dc.title Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 31843852
dc.relation.publisherversion https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2019-033712
dc.type.version info:eu-repo/semantics/publishedVersion
dc.identifier.doi 10.1136/bmjopen-2019-033712
dc.journal.title BMJ Open


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento-NoComercial 4.0 Internacional Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento-NoComercial 4.0 Internacional

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta